Efonidipine structure.svg
Clinical data
Trade namesLandel (ランデル)
AHFS/Drugs.comInternational Drug Names
Routes of
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
  • 2-(Phenyl-(phenylmethyl)amino)ethyl 5-(5,5-dimethyl-2-oxo-1,3-dioxa-2λ5-phosphacyclohex-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass631.666 g·mol−1
3D model (JSmol)
  • O=P1(OCC(CO1)(C)C)C/4=C(/N\C(=C(\C(=O)OCCN(c2ccccc2)Cc3ccccc3)C\4c5cccc([N+]([O-])=O)c5)C)C
  • InChI=1S/C34H38N3O7P/c1-24-30(33(38)42-19-18-36(28-15-9-6-10-16-28)21-26-12-7-5-8-13-26)31(27-14-11-17-29(20-27)37(39)40)32(25(2)35-24)45(41)43-22-34(3,4)23-44-45/h5-17,20,31,35H,18-19,21-23H2,1-4H3 ☒N
 ☒NcheckY (what is this?)  (verify)

Efonidipine (INN) is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel (ランデル). The drug blocks both T-type and L-type calcium channels.[1] Drug Controller General of India (DCGI) has approved the use of efonidipine in India.[2] It is launched under the brand name "Efonta" (Ajanta Pharma Ltd, India) & Efnocar" (Zuventus Health care ltd, India).

Structure Activity Relationship

Efonidipine is a dual Calcium Channel Blocker (L & T-type). It has a unique chemical structure. The phosphonate moiety (Figure 1) at the C5 position of the dihydropyridine ring is considered to be important for the characteristic pharmacological profile of the drug. (figure-1)

Figure-1:Efonidipine: Chemical Structure
Figure-1:Efonidipine: Chemical Structure

Mechanism of action

Efonidipine, a new generation dihydropyridine (DHP) calcium channel blocker, inhibits both L-type and T-type calcium channels.[1]




Peak plasma concentration is achieved in about 1.5 to 3.67 hours after administration. Half life is approximately 4 hours. The pharmacokinetic parameters of Efonidipine are depicted in Table-1.

Table 1: PK Parameters in Adult Healthy Male Subjects

Variable Efonidipine
Mean Range
Cmax(ng/ml) 36.25 9.66-66.91
Tmax (hour) 2.59 1.50-3.67
T1/2 (hour) 4.18 2.15-6.85


Efonidipine is primarily metabolized in the liver. The important metabolites are N-dephenylated Efonidipine (DPH), deaminated Efonidipine (AL) and N-debenzylated Efonidipine (DBZ). DBZ and DPH exhibit activity as calcium antagonists. The vasodilating properties of DBZ and DPH were about two-thirds and one-third respectively than that of the parent compound. Results suggest that the majority of the pharmacological effect after oral dosing of Efonidipine hydrochloride in man is due to unchanged compound and its metabolites make a small contribution to the pharmacological effect.[9]


Biliary route is the main pathway of excretion. No significant amount of unchanged drug was excreted in urine. In the urine collected for 24 h after an oral dosing, 1.1 % of the dose was excreted as deaminated Efonidipine, and 0.5% as a pyridine analogue of deaminated Efonidipine.




Drug Interactions

Adverse Drug Reactions

The common side effects are hot flushes, facial flushing and headache. In addition, elevation in serum total cholesterol, ALT (SGPT), AST (SGOT) and BUN may occur. Frequent urination, pedal edema, increased triglycerides occurs in less than 0.1%.[10]

Lesser incidence of pedal edema (< 0.1%)

One common adverse effect of the L-type Ca2+ channel blockers like Amlodipine is vasodilatory Pedal edema. Combined L-/T-type Ca2+ channel blockers, such as Efonidipine, display antihypertensive efficacy similar to their predecessors (Amlodipine) with much less propensity of pedal edema formation. Efonidipine equalizes the hydrostatic pressure across the capillary bed through equal arteriolar and venular dilatation, thus reducing vasodilatory edema. These incremental microcirculatory benefits of efonidipine over the conventional L-type Ca2+ channel blockers (Amlodipine) are likely attributed to their additional T-type Ca2+ channel blocking properties and the increased presence of T-type Ca2+channels in the microvasculature (e.g. arterioles, capillaries, venules etc.).[11]

Among the CCBs, Efonidipine (<0.1%)[10] has lowest incidence of pedal edema compared to amlodipine ( 5-16%),[12] cilnidipine (5%),[13] benidipine (5%)[14]

Use in special population

Administration to elderly

The drug should be started at low dose (20 mg/day) in elderly. Patient should be carefully observed for development of hypo-tension. Dose may be halved if there is intolerance to the 20 mg/day dosage regimen.

Pregnancy and lactation

The drug should not be administered to pregnant women and women suspected of being pregnant. Administration to lactating women should be avoided unless benefit significantly surpasses the risk to the child. Mothers on Efonidipine treatment should avoid breast feeding.

Pediatric use

Safety of Efonidipine in low birth weight infants, newborns, infants and children has not been established. 


  1. ^ a b c Tanaka H, Shigenobu K (2002). "Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels". Cardiovascular Drug Reviews. 20 (1): 81–92. doi:10.1111/j.1527-3466.2002.tb00084.x. PMID 12070536. S2CID 32370329.
  2. ^ "Recommendations" (PDF). 34th SEC (Cardiovascular & Renal) Meeting. Central Drugs Standard Control Organization, Government of India. 11 August 2016. Archived from the original (PDF) on 2017-11-07. Retrieved 2019-08-04.
  3. ^ Masumiya H, Shijuku T, Tanaka H, Shigenobu K (May 1998). "Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect". European Journal of Pharmacology. 349 (2–3): 351–7. doi:10.1016/s0014-2999(98)00204-0. PMID 9671117.
  4. ^ a b Masuda Y, Tanaka S (June 1994). "Efonidipine hydrochloride: a new calcium antagonist". Cardiovascular Drug Reviews. 12 (2): 123–35. doi:10.1111/j.1527-3466.1994.tb00287.x.
  5. ^ a b Ikeda K, Isaka T, Fujioka K, Manome Y, Tojo K (2012). "Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists". International Journal of Endocrinology. 2012: 519467. doi:10.1155/2012/519467. PMC 3477571. PMID 23097668.
  6. ^ Hayashi K, Homma K, Wakino S, Tokuyama H, Sugano N, Saruta T, Itoh H (2010). "T-type Ca channel blockade as a determinant of kidney protection". review. The Keio Journal of Medicine. 59 (3): 84–95. doi:10.2302/kjm.59.84. PMID 20881449.
  7. ^ a b Hayashi M, Yamaji Y, Nakazato Y, Saruta T (September 2000). "The effects of calcium channel blockers on nuclear factor kappa B activation in the mesangium cells". Hypertension Research. 23 (5): 521–5. doi:10.1291/hypres.23.521. PMID 11016808.
  8. ^ Sugano N, Sugano N, Wakino S, Tatematsu S, Homma K, Yoshioka K, et al. (December 2006). "Role of T-type Ca2 channels (TCCs) as a determinant of Rho-kinase activation and epithelial-mesenchymal transition (EMT) in renal injury". Journal of Hypertension. 24 (suppl 6): 128.
  9. ^ Nakabeppu H, Asada M, Oda T, Shinozaki Y, Yajima T (February 1996). "Plasma and urinary metabolites of efonidipine hydrochloride in man". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 26 (2): 229–39. doi:10.3109/00498259609046703. PMID 8868006.
  10. ^ a b 医療用医薬品 : ランデル. Kyoto Encyclopedia of Genes and Genomes.
  11. ^ Ge W, Ren J (April 2009). "Combined L-/T-type calcium channel blockers: ready for prime time". Hypertension. 53 (4): 592–4. doi:10.1161/HYPERTENSIONAHA.108.127548. PMID 19237678.
  12. ^ Osterloh IH (1991). "An update on the safety of amlodipine". Journal of Cardiovascular Pharmacology. 17 Suppl 1: S65–8. doi:10.1097/00005344-199117001-00020. PMID 16296714.
  13. ^ 医療用医薬品 : アテレック. Kyoto Encyclopedia of Genes and Genomes.
  14. ^ 医療用医薬品 : コニール. Kyoto Encyclopedia of Genes and Genomes.

Further reading